Head-to-head comparison of Subcutaneous Tocilizumab versus Abatacept for Rheumatoid arthritis : prospective, randomized trial.
Not Applicable
Recruiting
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000015175
- Lead Sponsor
- St.Marianna University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
1.Past history of hypersensitivity to Abatacept or Tocilizumab. 2.Serious infection. 3.Active tuberculosis. 4.Lymphocytes count less than 500/microlitter. 5.Past history of infection of HCV, HBV, HIV, or HTLV-1. 6.History of TNF inhibitor administration within three months at registration. 7.An inappropriate case for the study based on the assessment by the doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of HAQ and CDAI remission rate at 52 weeks.
- Secondary Outcome Measures
Name Time Method